Angela Koehler

Koehler was an undergraduate student in biochemistry at Reed College. She worked on structural studies of proteins that recognize nucleic acids, including transfer RNA and DNA. She moved to Harvard University as a doctoral researcher, where she worked alongside Stuart Schreiber on strategies to understand the interactions between proteins and molecules.

Koehler joined the chemical biology program at the Broad Institute, where she was made group leader for chemical genetics. Koehler develops time-sensitive chemical tools to understand the dynamics of transcriptional regulation. Before the work of Koehler it was understood that transcription factors were "undruggable", as their inherent structural disorder compromised the binding of small-molecule ligands. Her research looks to develop small-molecule probes that modify proteins, which can, in turn, tune gene expression.

Koehler is on the faculty at the Koch Institute for Integrative Cancer Research. She has founded several companies, including Ligon Discovery, a drug discovery company focused on small-molecule microarrays, Kronos Bio, a cancer therapeutics accelerator and 76Bio, a biotechnology company that looks to develop targeted protein degraders.